The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT07610369
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Psilocybin (drug) — DRUG
    Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
  • Psilocybin (drug) — DRUG
    Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

Study Details

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Key Dates

Start date
May 31, 2026
Status verified
May 2026
Primary completion
May 31, 2030
Completion
May 31, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Psilocybin Administration Session 1
    Participants will receive one dose of psilocybin ranging from low ("microdose") to high in a monitored setting with preparation sessions before and integration sessions after.
  • Experimental: Psilocybin Administration Session 2
    Participants will receive one dose of psilocybin ranging from low ("microdose") to high in a monitored setting with preparation sessions before and integration sessions after.

Primary Outcome Measure

Change in depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: Baseline to 30 days after first drug dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Yale UniversityNew HavenConnecticut06510
Sophie Holmes, PhD
[email protected]
203-685-4066
Sophie Holmes, PhD (PRINCIPAL_INVESTIGATOR)
Gerard Sanacora, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
Yale University· New Haven, CT

Related Studies